Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Liposarcoma × pemigatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Cholangiocarcinoma 6 Gastrointestinal Neoplasms 3 Carcinoma, Transitional Cell 3 Breast Neoplasms 3 Pancreatic Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Carcinoma 2 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Solid Tumor, Miscellaneous 1 Solid Tumor 1 Sarcoma 1 Recurrence 1 Non-Muscle Invasive Bladder Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Lymphoma, Mantle-Cell 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma, B-Cell 1 Lung Neoplasms 1 Locally Advanced Unresectable Gastric Cancer 1 Liposarcoma 1 Leukemia, Myeloid, Acute 1 Hematologic Neoplasms 1 Gastrointestinal Stromal Tumors 1 Fibroblast Growth Factors (FGFs)/Fibroblast Growth Factor Receptors (FGFRs) Genetic Aberration Gastric Cancer, INCB054828, Paclitaxel 1 Digestive System Neoplasms 1 Advanced Non-Small Cell Lung Cancer 1 Advanced Non Small Cell Lung Cancer 1

Interventions

Radiotherapy 8 Doxorubicin 7 pazopanib 5 palbociclib 4 Trabectedin 4 Gemcitabine 4 ribociclib 3 pembrolizumab 3 eribulin 3 selinexor 2 liposomal doxorubicin 2 avelumab 2 Sunitinib 2 Radiation Dose Hypofractionation 2 Magnetic Resonance Spectroscopy 2 Immunoglobulin G 2 Ifosfamide 2 Docetaxel 2 Cyclophosphamide 2 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2 zimberelimab 1 temsirolimus 1 sotigalimab 1 sodium thiosulfate 1 sitravatinib 1 silmitasertib 1 sargramostim 1 romidepsin 1 regorafenib 1 plitidepsin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06389799 2025-08-28

PERELI

Lund University Hospital

Phase 2 Recruiting

Liposarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡